S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.59 (-0.22%)
AAPL   114.20 (-0.66%)
MSFT   207.40 (-0.97%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,149.65 (-0.77%)
TSLA   420.00 (-0.28%)
NVDA   530.47 (+1.74%)
BABA   277.30 (+0.47%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.90 (+4.38%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.61 (-1.20%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.54 (-0.36%)
BA   164.20 (-1.13%)
BAC   23.82 (-1.12%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.59 (-0.22%)
AAPL   114.20 (-0.66%)
MSFT   207.40 (-0.97%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,149.65 (-0.77%)
TSLA   420.00 (-0.28%)
NVDA   530.47 (+1.74%)
BABA   277.30 (+0.47%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.90 (+4.38%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.61 (-1.20%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.54 (-0.36%)
BA   164.20 (-1.13%)
BAC   23.82 (-1.12%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.59 (-0.22%)
AAPL   114.20 (-0.66%)
MSFT   207.40 (-0.97%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,149.65 (-0.77%)
TSLA   420.00 (-0.28%)
NVDA   530.47 (+1.74%)
BABA   277.30 (+0.47%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.90 (+4.38%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.61 (-1.20%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.54 (-0.36%)
BA   164.20 (-1.13%)
BAC   23.82 (-1.12%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.59 (-0.22%)
AAPL   114.20 (-0.66%)
MSFT   207.40 (-0.97%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,149.65 (-0.77%)
TSLA   420.00 (-0.28%)
NVDA   530.47 (+1.74%)
BABA   277.30 (+0.47%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.90 (+4.38%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.61 (-1.20%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.54 (-0.36%)
BA   164.20 (-1.13%)
BAC   23.82 (-1.12%)
Log in
NASDAQ:DBVT

DBV TECHNOLOGIE/S Stock Forecast, Price & News

$1.73
-0.01 (-0.57 %)
(As of 09/29/2020 03:57 PM ET)
Add
Compare
Today's Range
$1.71
Now: $1.73
$1.75
50-Day Range
$1.58
MA: $2.04
$2.34
52-Week Range
$1.57
Now: $1.73
$13.49
Volume8,345 shs
Average Volume479,804 shs
Market Capitalization$190.05 million
P/E RatioN/A
Dividend YieldN/A
Beta2.27
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Read More
DBV TECHNOLOGIE/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DBVT
CUSIPN/A
Phone33-1-55-42-78-78

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.75 million
Book Value$2.11 per share

Profitability

Miscellaneous

Employees244
Market Cap$190.05 million
Next Earnings DateN/A
OptionableOptionable
$1.73
-0.01 (-0.57 %)
(As of 09/29/2020 03:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DBVT News and Ratings via Email

Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions

How has DBV TECHNOLOGIE/S's stock price been impacted by COVID-19?

DBV TECHNOLOGIE/S's stock was trading at $7.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DBVT stock has decreased by 75.6% and is now trading at $1.73.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of DBV TECHNOLOGIE/S?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for DBV TECHNOLOGIE/S
.

How were DBV TECHNOLOGIE/S's earnings last quarter?

DBV TECHNOLOGIE/S (NASDAQ:DBVT) announced its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.35.
View DBV TECHNOLOGIE/S's earnings history
.

What price target have analysts set for DBVT?

11 brokerages have issued 1-year target prices for DBV TECHNOLOGIE/S's shares. Their forecasts range from $2.00 to $14.00. On average, they expect DBV TECHNOLOGIE/S's stock price to reach $6.42 in the next twelve months. This suggests a possible upside of 270.9% from the stock's current price.
View analysts' price targets for DBV TECHNOLOGIE/S
.

Are investors shorting DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 247,200 shares, a decline of 72.7% from the August 31st total of 906,600 shares. Based on an average daily trading volume, of 551,400 shares, the days-to-cover ratio is currently 0.4 days.
View DBV TECHNOLOGIE/S's Short Interest
.

Who are some of DBV TECHNOLOGIE/S's key competitors?

What other stocks do shareholders of DBV TECHNOLOGIE/S own?

Who are DBV TECHNOLOGIE/S's key executives?

DBV TECHNOLOGIE/S's management team includes the following people:
  • Dr. Pierre-Henri Benhamou, Co-Founder & Non-Exec. Chairman (Age 64)
  • Mr. David Schilansky, Deputy CEO & CFO (Age 44)
  • Dr. Laurent Martin, Chief Devel. Officer (Age 52)
  • Mr. Daniel Tassé, CEO & Director (Age 59)
  • Mr. Bertrand Dupont, Co-Founder & CTO (Age 67)

What is DBV TECHNOLOGIE/S's stock symbol?

DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT."

How do I buy shares of DBV TECHNOLOGIE/S?

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DBV TECHNOLOGIE/S's stock price today?

One share of DBVT stock can currently be purchased for approximately $1.73.

How big of a company is DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S has a market capitalization of $190.05 million and generates $14.75 million in revenue each year. The company earns $-172,020,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe.

What is DBV TECHNOLOGIE/S's official website?

The official website for DBV TECHNOLOGIE/S is www.dbv-technologies.com.

How can I contact DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.